U.S., July 30 -- An application to own the trademark for 'CTX213' has been filed on Jan. 13, 2025.
Owner(s):
CRISPR Therapeutics AG; Baarerstrasse 14, , SWITZERLAND
Goods and/or Services:
For: Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes
Class(es): 005, 006, 018, 044, 046, 051, 052
For: gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment ...